Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -1462.12% is 2580% below its 5-year average of -54.56%, near the low end of its 5-year range (-1462.12%–6.10%).
339.66% below its 12-month average of -332.56%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -584.42%.
RETURN ON EQUITY (ROE)
-1462.12%
RETURN ON EQUITY (ROE) AVG TTM
-332.56%
RETURN ON EQUITY (ROE) AVG 3Y
-128.49%
RETURN ON EQUITY (ROE) AVG 5Y
-54.56%
RETURN ON EQUITY (ROE) AVG 10Y
-67.17%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-339.66%
CURRENT VS 3Y AVG
-1037.94%
CURRENT VS 5Y AVG
-2579.62%
CURRENT VS 10Y AVG
-2076.67%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-3380.41%
vs the sector median at left
Syndax Pharmaceuticals, Inc.
Market Cap
$1.54B
Return on Equity (ROE)
-1462.12%
TTM Avg
-332.56%
3Y Avg
-128.49%
5Y Avg
-54.56%
Market Cap
$1.54B
Return on Equity (ROE)
28.97%
TTM Avg
13.25%
3Y Avg
22.73%
5Y Avg
32.77%
Market Cap
$1.57B
Return on Equity (ROE)
-60.17%
TTM Avg
-20.40%
3Y Avg
-40.27%
5Y Avg
-36.46%
Market Cap
$1.50B
Return on Equity (ROE)
45.63%
TTM Avg
28.57%
3Y Avg
-115.12%
5Y Avg
-36.89%
Market Cap
$1.50B
Return on Equity (ROE)
27.24%
TTM Avg
-16.62%
3Y Avg
-27.07%
5Y Avg
-49.65%
Market Cap
$1.59B
Return on Equity (ROE)
-67.40%
TTM Avg
-53.05%
3Y Avg
2.62%
5Y Avg
2.10%
Market Cap
$1.49B
Return on Equity (ROE)
-32.43%
TTM Avg
-24.32%
3Y Avg
8.11%
5Y Avg
8.11%
Market Cap
$1.48B
Return on Equity (ROE)
25.87%
TTM Avg
21.38%
3Y Avg
13.81%
5Y Avg
16.13%
Market Cap
$1.60B
Return on Equity (ROE)
-77.83%
TTM Avg
1723.94%
3Y Avg
818.18%
5Y Avg
546.13%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.54B | -1462.12% | -332.56% | -128.49% | -54.56% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 28.97% | 13.25% | 22.73% | 32.77% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | -60.17% | -20.40% | -40.27% | -36.46% |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 45.63% | 28.57% | -115.12% | -36.89% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 27.24% | -16.62% | -27.07% | -49.65% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -67.40% | -53.05% | 2.62% | 2.10% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | -32.43% | -24.32% | 8.11% | 8.11% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 25.87% | 21.38% | 13.81% | 16.13% |
| uniQure N.V. (QURE)vs › | $1.60B | -77.83% | 1723.94% | 818.18% | 546.13% |
| GH Research PLC (GHRS)vs › | $1.48B | -17.32% | -19.51% | -16.07% | -12.58% |
ROE
-1462.1%
ROA
-31.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -584.42% |
| 2025-12-31 | -441.62% |
| 2025-09-30 | -269.93% |
| 2025-06-30 | -212.79% |
| 2025-03-31 | -154.01% |
| 2024-12-31 | -110.63% |
| 2024-09-30 | -81.07% |
| 2024-06-30 | -60.80% |
| 2024-03-31 | -48.92% |
| 2023-12-31 | -37.78% |
| 2023-09-30 | -49.02% |
| 2023-06-30 | -40.08% |
| 2023-03-31 | -35.20% |
| 2022-12-31 | -31.95% |
| 2022-09-30 | -4.12% |
| 2022-06-30 | 0.23% |
| 2022-03-31 | 4.13% |
| 2021-12-31 | 6.10% |
| 2021-09-30 | -46.08% |
| 2021-06-30 | -42.64% |
| 2021-03-31 | -37.53% |
| 2020-12-31 | -29.01% |
| 2020-09-30 | -50.57% |
| 2020-06-30 | -40.05% |
| 2020-03-31 | -106.49% |
| 2019-12-31 | -177.36% |
| 2019-09-30 | -138.24% |
| 2019-06-30 | -118.30% |
| 2019-03-31 | -100.35% |
| 2018-12-31 | -139.43% |
| 2018-09-30 | -115.49% |
| 2018-06-30 | -102.31% |
| 2018-03-31 | -77.32% |
| 2017-12-31 | -58.28% |
| 2017-09-30 | -54.30% |
| 2017-06-30 | -47.92% |
| 2017-03-31 | -64.88% |
| 2016-12-31 | -52.86% |
| 2016-09-30 | -41.48% |
| 2016-06-30 | -29.82% |
| 2016-03-31 | -25.95% |
| 2015-12-31 | -36.16% |
| 2015-09-30 | -31.66% |
| 2014-06-30 | -411.35% |
| 2014-03-31 | -202.23% |
| 2013-12-31 | -119.60% |
